NAVIDEA BIOPHARMACEUTICALS, INC. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4f193d9d-6afe-4fd8-a9ff-78560d0cb823/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-15.2M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-008054 |
| FY 2021 | $-11.7M | 2021-01-01 – 2021-12-31 | evidence 0001437749-23-008054 |
| FY 2016 | $-14.3M | 2016-01-01 – 2016-12-31 | evidence 0001654954-17-002915 |
| FY 2015 | $-27.6M | 2015-01-01 – 2015-12-31 | evidence 0001654954-17-002915 |
| FY 2014 | $-35.7M | 2014-01-01 – 2014-12-31 | evidence 0000810509-15-000003 |
| FY 2013 | $-42.7M | 2013-01-01 – 2013-12-31 | evidence 0001445305-14-001051 |
| FY 2012 | $-29.2M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-016705 |
| FY 2011 | $5.6M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-013346 |
| FY 2010 | $-50.0M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-013346 |
| FY 2009 | $-39.6M | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-013346 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NAVIDEA BIOPHARMACEUTICALS, INC. — all facts · Revenue · Operating Income